Detection and characterization of circulating microvesicles containing Shiga toxin type 2 (Stx2) in a rat model of Hemolytic Uremic Syndrome
Preprint
Abstract
Shiga toxin (Stx) producing Escherichia coli (STEC) are foodborne pathogens that release Stx and may develop Hemolytic Uremic Syndrome (HUS). Stx causes endothelial cell damage and leads to platelets deposition and thrombi formation within the microvasculature. It has been described that Stx activates blood cells and induces the shedding of proinflammatory and prothrombotic microvesicles (MVs) containing the toxin. In this sense, it has been postulated that MVs containing Stx2 (MVs-Stx2+) can contribute to the physiopathology of HUS, allowing Stx to reach the target organs and evading the immune system. In this work, we propose that circulating MVs-Stx2+ can be a potential biomarker for the diagnosis and prognosis of STEC infections and HUS progression. In this regard, we developed a rat HUS model by the intreperitoneal injection of a sublethal dose of Stx2 and observed: decrease in body weight, increase of creatinine and urea levels, decrease of creatinine clearance and histological renal damages. After characterization of renal damages we investigated circulating total MVs and MVs-Stx2+ by flow cytometry at different times after Stx2 injection. Additionally, we evaluated the correlation of biochemical parameters such as creatinine and urea in plasma with MVs-Stx2+. As a result, we found a significant circulation of Mvs-Stx2+ at 96 hours after Stx2 injection, nevertheless no correlation with creatinine and urea plasma levels were detected. Our results suggest that MVs-Stx2+ may be an additional biomarker for the characterization and diagnosis of HUS progression. Further analysis is required in order to validate MVs-Stx2+ as biomarker of the disease.Keywords
All Related Versions
- Published version: Toxicon, 236, 107349.
This publication has 32 references indexed in Scilit:
- Extracellular microvesicles/exosomes: discovery, disbelief, acceptance, and the future?Leukemia, 2020
- Shiga toxin-producing Escherichia coli in household members of children with hemolytic uremic syndromeEuropean Journal of Clinical Microbiology & Infectious Diseases, 2019
- Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndromePediatric Nephrology, 2018
- Shedding light on the cell biology of extracellular vesiclesNature Reviews Molecular Cell Biology, 2018
- Microvesicles in Autoimmune Diseases2016
- Shiga Toxin Producing Escherichia coliClinics In Laboratory Medicine, 2015
- Microparticle analysis in disorders of hemostasis and thrombosisCytometry Part A, 2015
- Microvesicles and diabetic complications — novel mediators, potential biomarkers and therapeutic targetsActa Pharmacologica Sinica, 2014
- Development of an experimental hemolytic uremic syndrome in ratsPediatric Nephrology, 2008
- Epidemic hemolytic-uremic syndrome in childrenKidney International, 1997